poisar

Stocks · News reference

Ionis Pharmaceuticals Announces Positive Two-Year Data for Diranersen in Alzheimer's Disease

Fiscal.ai

Ionis Pharmaceuticals and its partner Biogen reported new two-year data from the Phase 2 CELIA study showing clinical benefit for diranersen in early Alzheimer's disease.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading